Penile Device usage for Cystometry in men with Stress Urinary Incontinence- PaceyCuff application.

Southhampton Bristol Group Cystometry Research

The problem of investigation in patients with incontinence is that virtually all urine produced leaks out of the bladder and therefore cannot be used for traditional investigative Cystometry. This study answered a few questions that are important.

1. The clamping did allow conventional testing in 30/166 post prostatectomy patients studied.n Use of the clamp did not affect vesicle filling or conduct of the test.

2. Pressure flow study flow rates were not affected when compared with the main study non-clamp group but the detrusor pressure was noted to be lower in the clamp group suggesting weaker bladder contraction.

3. The penile clamp use did not cause vesical-ureteral reflux as proved by contrast cystograms. This is important for those patients using urethral control devices as infection or damage to the proximal urinary tract could follow active reflux.

Comment:

The Bristol Group used an archaic Thomson-Walker Clamp which we would submit was less than ideal because of the general Clamp problem of circulatory impairment.

This Clamp was used for short term so this was not considered to be important.

Generally this study is good news for the Urethral Control devices because of the lack of ureteral reflux.

paceycuff.com

Sh a r a f , A . , F ader, M., Macaulay, M., & Drake, M. (2018). Use of an

occlusive penile clamp during filling cystometry in men with symptoms of

stress urinary incontinence. Lower Urinary Tract Symptoms.

https://doi.org/10.1111/luts.

Pacey Medtech Customer Support

Pacey Medtech Great Customer Support

The nature of medical device innovation is complex and challenging because Clinical History can be so different depending on Surgery , Radiotherapy, natural anatomy which varies.

To design a device that aims to preserve circulation requires that adjustability is able to serve a wide range of users.

Customer support has been proven to give the guidance necessary for successful use on many occasions and  resulted in many commendations of our capable support team. The goal is always to be sure to give maximal support so that customers will be able to rely on our  devices.

We try very hard to not  make you hold while seeking our help. Call 1-877-377-2239 for a 5 star support team.

                                                                 PaceyCuff.com

Innovation Is our Trademark- Standby for more exciting Product upgrades in 2020.

Full ahead when you are using the PaceyCuff ,

PowerSleeve

and

PaceyCuff Guard .paceycuff.com

Get serious control with our great tools. join the Pacey Medtech email system to get word about our continuously evolving products.

PaceyCuff Use for Parkinsons Disease

Incontinence in Neurological Disorders Parkinson's Disease-  Neurogenic Bladder

The Problem:

    Patients with advancing Parkinson's Syndrome have several issues affecting the bladder function. With age in a normal population the incidence of incontinence gets higher in proportion to age of the individual. The incidence increases from 11%overall to 31 % in older men.

    The prostate enlarges over time and often restricts urine flow in the elderly. This results in

 increasing amounts of retention of urine in the bladder and resulting overflow incontinence with stress. The treatment of this cause is usually some method of removing the offending prostate tissue to increase flow. This does allow better emptying of the bladder but in itself can result in incontinence in only 1% of patients normally. 

   Parkinson's Neurogenic bladder is failure of the neurological control mechanisms.

Management with a PaceyCuff device will depend on the exact applications which must be thought out and executed with care.

Fig.1       PaceyCuff Ultra (tm)

Fig. 2     PaceyCuff Guard clothing protector

Known usage:
   1. PaceyCuff specific use for ambulation of the patient for physical therapy or xray.
   2. PaceyCuff  specific use for social outings.
   3. PaceyCuff use for prevention of bed wetting which requires a specific protocol for regular                     release. 

\

PaceyCuff System Components

PaceyCuff System Essential Components

The importance of components of the current PaceyCuff System are as follows:

a. The  PaceyCuff Urethral Control Device is now the Premier urethral control device available. The recent changes now beginning to be incorporated include a Neoprene Pad system that is closed cell non-absorptive foam with excellent memory and resistance to deformation with prolonged use. This Neoprene will cover the tops and bottoms on the patient contact surfaces. The strap will also be replaced with a ruggedized Neoprene product. The 75 year history of Neoprene in the SCUBA wear garments shows extreme durability. The new compression tab will also appear soon to allow more convenient closure of the device.

b. The PaceyCuff Guard is an essential asset for catching drips and providing daily security as well as night use with absorbables when the PaceyCuff is not in use. 

c. The PaceyCuff Power Sleeve is a device that collects and contains the skin and allows a consistent target for PaceyCuff application which increases continence as it prevents pinching.
The use of a petroleum gel like ,Vaseline, gives great comfort and skin protection when one is using the PaceyCuff System.

d. B3NTH Briefs are a convenient addition to your toolkit that will provide a generous pocket for use of the PaceyCuff Guard.

Prostate Cancer News- Important Therapeutic study on Radiation combined with Hormone Antagonist

Carrie C, Magné N, Burban-Provost P, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-mont follow-up of a phase 3, randomised trial [published online October 16, 2019]. Lancet Oncol.  doi: 10.1016/S1470-2045(19)30486-3.

The GETUG-AFU 16 trial enrolled patients from October 19, 2006 to March 30, 2010. Dr Carry and his collaborators randomly assigned 743 men with to receive radiotherapy alone (374 patients) or radiotherapy in addition to goserelin (369 patients). One patient in the radiotherapy alone group later withdrew consent, leaving 373 patients in that group. The median follow-up was 112 months. In the first analysis of the trial, which was published in 2016, only the first progression event was collected, so MFS could not be analyzed, the authors noted.

paceycuff.com